Delmarva

The Centers for Medicare and Medicaid Services and the U.S. Department of Health and Human Services’ Office of Inspector General have provided certain waivers of federal fraud and abuse laws in connection with participation during the Implementation Period in the Comprehensive Kidney Care Contracting (“CKCC”) Option of the Kidney Carse Choices (“KCC”) Model (“KCC Implementation Period Waivers”). In accordance with such Waivers, the KCE provides notice that the Implementation Period KCE Activities arrangement described below is being provided under the protection of the KCC Implementation Period Waivers.

Implementation Period KCE Activities: The Board of Managers of Delmarva Kidney Care Entity, LLC (the “CE”) has duly authorized the following arrangement and has made a bona fide determination that this arrangement is reasonably related to the performance of KCE Activities during the Implementation Period because the arrangement is in preparation for and will promote the future accountability for the quality, cost, and overall care for KCE Beneficiaries. As of October 19, 2021, the KCE has engaged BIO-MEDICAL APPLICATIONS OF WEST VIRGINIA, INC., a KCE Preferred Provider, to provide certain services and items in preparation for the start of the Performance Year. Such services and items include care coordination and management services, education related to performance under a risked-based financial arrangement, and information technology to improve care processes and to prepare for the assumption of financial risk under the KCC Model.

The KCE will publicly disclose on this website additional arrangements that qualify for the KCC Implementation Period Waivers as they are authorized by its governing board, in compliance with public disclosure requirements.